-
News from the Appalachian Node: CPDD Participation
-
News from the Pacific Northwest Node: Mary Hatch Receives Award; Two New Publications about CTN-0082
PNW Node Co-Investigator Mary Hatch Receives UW Departmental Award On June 17, 2026, Mary Hatch, PhD, was awarded the UW Department of Psychiatry & Behavioral Sciences Wayne J. Katon Outstanding Research Mentor Award, which recognizes a faculty member who has demonstrated excellence in research mentoring of faculty members and trainees, including students, residents, fellows, and postdocs. Faculty mentors selected for this award have demonstrated a sustained commitment to fostering the creative, scholarly, professional and personal development of their mentees. Dr. Hatch is Co-Investigator of the NIDA National Drug Abuse Treatment Clinical Trials Network’s Pacific Northwest Node and Director of the Clinical Trials Consultation and Technical Assistance Program (C-TAP). Congratulations, Dr. Hatch! The PNW Node has two new publications out, both related to CTN-0082: “Not a monolith”: Type-specific MOUD awareness and rural willingness among direct service providers and clients. Laschober TC, et al. Poster presented at the College on Problems of Drug Dependence (CPDD) annual meeting, June 14-17, 2026. This poster describes the results of a survey of CBO providers and clients across 13 Southern U.S. CBOs (FL, GA, LA, MS, and TN) that found that, compared with methadone, buprenorphine and naltrexone awareness was lower for both providers and clients, though providers were more aware of all types of medications for opioid use disorder (MOUD) than clients. Additionally, providers reported greater willingness to refer for buprenorphine and naltrexone than clients reported willingness to be referred. These types of misalignments can hinder MOUD uptake and contribute to high overdose rates and limited MOUD access in…
-
New in the Library (May – June 2026)
Here are the latest items added to the CTN Dissemination Library for May – June 2026 (this post will be updated as new items come in): Probability of fentanyl adulteration in cocaine selectively decreases cocaine demand. Nunez C, et al. Experimental and Clinical Psychopharmacology 2026;34(2):207-215. (Primary outcomes for CTN-0130) Undervaluing nondrug rewards or overvaluing cocaine? Cocaine demand relates to cocaine use severity more strongly than anhedonia in individuals with cocaine use disorder. Nunez C, et al. Experimental and Clinical Psychopharmacology 2026;33(1):91-99. Applying machine learning in predicting medication treatment outcomes for opioid use disorder. Balise RR, et al. Journal of Substance Use and Addiction Treatment 2026;183:209847. “Not a monolith”: Type-specific MOUD awareness and rural willingness among direct service providers and clients. Laschober TC, et al. Poster presented at the College on Problems of Drug Dependence (CPDD) annual meeting, June 14-17, 2026. (CTN-0082) Fentanyl overdose history and cocaine use severity are associated with how people mitigate risks of fentanyl-adulterated cocaine. Anighoro B, et al. Substance Use & Misuse 2026 (in press). (CTN-0130) Perceived effect of the COVID-19 pandemic on substance use and interest in medications for opioid use disorder and naloxone among people who use opioids in the Southern United States. Laschober TC, et al. Journal of Prevention and Health Promotion 2026 (in press). (CTN-0082) Emergency department-initiated standard versus high-dose buprenorphine induction (ENVISION): A randomised clinical trial protocol. Hawk K, et al. BMJ Open 2026;16(6):e113762. (CTN-0145) Characterization of patients declining to participate in opioid overdose prevention clinical research in an emergency…
-
HHS Request for Comment on Chronic Disease of Addiction (Deadline July 5)
The US Department of Health and Human Services (HHS) is seeking comment in response to an RFI related to substance research, policy, and strategies to improve the prevention, treatment, and recovery of the chronic disease of addiction and mental illness and “how to promote the Great American Recovery Initiative.” The initiative includes goals to: Learn more and submit your comments here by July 5, 2026
